Loading patent…
AssigneeCell Signaling Technology, Inc.
InventorsMark Livingstone, Hong Ruan, Robert Polakiewicz
Estimating the term…
The invention discloses two novel phosphorylation sites in human ATR kinase, serine 428 (Ser428) and serine 2317 (Ser2317) respectively, and provides reagents, including antibodies and AQUA peptides, that selectively bind to and/or detect ATR only when phosphorylated at one or more of these respective sites, but do not bind to ATR when not phosphorylated at these respective sites. Also provided are methods for determining the phosphorylation of ATR kinase in a biological sample, by using a detectable reagent that binds to ATR only when phosphorylated at Ser428 and/or Ser2317. Kits comprising the ATR (Ser428, Ser2317)-specific reagents of the invention are also provided.
An isolated antibody that binds to human Ataxia-Telangiectasia and Rad3-related (ATR) kinase when phosphorylated at serine 428 (SEQ ID NO:
A heavy-isotope labeled peptide (AQUA peptide) for the quantification of human ATR kinase, said labeled peptide comprising an ATR peptide encompassing either the serine 428 or serine 2317 phosphorylation site sequences (SEQ ID NO:
A method for detecting phosphorylated ATR kinase in a biological sample, said method comprising the steps of:
Dependencies are inferred from the claim text.